AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7645388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (SV)
Number of subjects: 27
Study 2787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 0
Study 2787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg
Number of subjects: 0
Study 2787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg
Number of subjects: 0
Study 2787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 2600 mg
Number of subjects: 0
Study 2787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and antacids (added after severe injuries)
Number of subjects: 0
Study 557318 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg subcutaneous physostigmine therapy (three sessions)
Number of subjects: 0
Study 557318 — intervention group
Group type: COMPARATOR
Intervention: Control injections (randomly interspersed sessions)
Number of subjects: 0
Study 31818516 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple potato extract (PPE)
Number of subjects: 17
Study 31699568 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels
Number of subjects: 1734
Study 31699568 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP ≥0.74 mg/L at 3 months
Number of subjects: 1734
Study 27459721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 83
Study 27459721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 25497995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (225-300 mg every 2 weeks)
Number of subjects: 0
Study 25497995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (every 4 weeks dosing regimen)
Number of subjects: 0
Study 25497995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (higher or lower doses)
Number of subjects: 0
Study 23482056 — intervention group
Group type: EXPERIMENTAL
Intervention: 70,000 IU once + 35,000 IU/week vitamin D3 (group PH)
Number of subjects: 28
Study 23482056 — intervention group
Group type: COMPARATOR
Intervention: 14,000 IU/week vitamin D3 (PL)
Number of subjects: 28
Study 23482056 — intervention group
Group type: EXPERIMENTAL
Intervention: 70,000 IU once + 35,000 IU/week vitamin D3 (NH)
Number of subjects: 28
Study 25427325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthwash for 2 weeks
Number of subjects: 60
Study 25427325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthwash with subgingival irrigation
Number of subjects: 60
Study 25427325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthwash
Number of subjects: 60
Study 18534685 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with somatic delusions
Number of subjects: 183
Study 18534685 — intervention group
Group type: COMPARATOR
Intervention: Patients without somatic delusions
Number of subjects: 183
Study 17351987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthroposophy art therapy (painting with water-based paints)
Number of subjects: 60
Study 17351987 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants with < or =2 sessions)
Number of subjects: 60
Study 15353002 — intervention group
Group type: COMPARATOR
Intervention: 15 g alcohol per day
Number of subjects: 51
Study 15353002 — intervention group
Group type: COMPARATOR
Intervention: 30 g alcohol per day
Number of subjects: 51
Study 15353002 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 51
Study 11294662 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 28
Study 9625847 — intervention group
Group type: EXPERIMENTAL
Intervention: Collecting duct carcinomas (CDC)
Number of subjects: 0
Study 9625847 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear cell renal cell carcinoma (cRCC)
Number of subjects: 0
Study 29374350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg mixed in 100 ml normal saline)
Number of subjects: 60
Study 29374350 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ml normal saline only)
Number of subjects: 60
Study 28732531 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching in the luteal phase prior to controlled ovarian hyperstimulation
Number of subjects: 900
Study 28732531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endometrial scratching)
Number of subjects: 900
Study 26287351 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 66
Study 26287351 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 66
Study 23007732 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted parenchyma transection (RF-PT)
Number of subjects: 75
Study 23007732 — intervention group
Group type: COMPARATOR
Intervention: Clamp-crushing parenchyma transection (CC-PT)
Number of subjects: 75
Study 19172293 — intervention group
Group type: EXPERIMENTAL
Intervention: FIGO grading system
Number of subjects: 334
Study 19172293 — intervention group
Group type: EXPERIMENTAL
Intervention: GOG grading system
Number of subjects: 334
Study 19172293 — intervention group
Group type: EXPERIMENTAL
Intervention: Silverberg grading system
Number of subjects: 334
Study 19172293 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance rates between grading systems
Number of subjects: 334
Study 17784972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) administered over six weekly sessions
Number of subjects: 22
Study 17784972 — intervention group
Group type: COMPARATOR
Intervention: Delayed cognitive-behavioural therapy (D-CBT) administered twice weekly over three weeks
Number of subjects: 22
Study 14996630 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 14996630 — intervention group
Group type: COMPARATOR
Intervention: Oral antiplatelet and antithrombotic therapies
Number of subjects: 0
Study 12056242 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using five different protocols
Number of subjects: 731
Study 9931764 — intervention group
Group type: COMPARATOR
Intervention: Electrostimulation therapy
Number of subjects: 0
Study 9931764 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 0
Study 8081671 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant seed oil (BCSO)
Number of subjects: 0
Study 8081671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2686259 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/h of ISDN
Number of subjects: 22
Study 2686259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 791583 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine
Number of subjects: 46
Study 791583 — intervention group
Group type: COMPARATOR
Intervention: chlorpheniramine maleate
Number of subjects: 46
Study 31262673 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in transition education program
Number of subjects: 123
Study 27859533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment-based approach (ART-based)
Number of subjects: 127
Study 27859533 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 127
Study 25727953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐h infusion of 0.5 g of imipenem every 6 h for 8 doses
Number of subjects: 10
Study 25727953 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐h infusion of 0.5 g of imipenem every 6 h for 8 doses
Number of subjects: 10
Study 25727953 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐h infusion of 1 g of imipenem every 6 h
Number of subjects: 10
Study 25727953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐h infusion of 1 g of imipenem every 6 h
Number of subjects: 10
Study 25727953 — intervention group
Group type: EXPERIMENTAL
Intervention: All simulated regimens (4‐h infusion)
Number of subjects: 10
Study 23478070 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 15mg once daily
Number of subjects: 59
Study 23478070 — intervention group
Group type: COMPARATOR
Intervention: Gefarnate (GFN) 50mg twice daily
Number of subjects: 59
Study 21673035 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG vaccination at birth
Number of subjects: 2320
Study 19317378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg at bedtime for 10 weeks
Number of subjects: 27
Study 19317378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg at bedtime
Number of subjects: 27
Study 17162041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol porcine collagen implant
Number of subjects: 206
Study 17162041 — intervention group
Group type: COMPARATOR
Intervention: No implant (control group)
Number of subjects: 206
Study 15503333 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition-weighted 31P-MR spectroscopy (AW-MRS)
Number of subjects: 8
Study 11522950 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-band EEG in autism
Number of subjects: 0
Study 11522950 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-band EEG in Williams syndrome
Number of subjects: 0
Study 11522950 — intervention group
Group type: COMPARATOR
Intervention: Comparison of autism and Williams syndrome
Number of subjects: 0
Study 9576159 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 70
Study 9576159 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 70
Study 7843479 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (elemental calcium 156 or 312 mg/day per os) and vitamin D3 (0.5 micrograms/3 day per os)
Number of subjects: 876
Study 3279745 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based fortified product (V-N)
Number of subjects: 2
Study 3279745 — intervention group
Group type: COMPARATOR
Intervention: Powdered milk (PUR)
Number of subjects: 2
Study 30851939 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 90
Study 28829227 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bout of moderate‐intensity treadmill exercise for 10, 20, 30, 45, or 60 minutes followed by a recovery period of 5, 15, or 30 minutes.
Number of subjects: 352
Study 28829227 — intervention group
Group type: COMPARATOR
Intervention: Acute exercise (vs. no exercise) for various durations and recovery periods.
Number of subjects: 352
Study 28829227 — intervention group
Group type: EXPERIMENTAL
Intervention: Different acute exercise durations and recovery periods.
Number of subjects: 352
Study 25772974 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (PA website and monthly tailored emails)
Number of subjects: 149
Study 25772974 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based intervention (12 sessions of group exercising)
Number of subjects: 149
Study 25772974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed intervention (combination of web- and center-based)
Number of subjects: 149
Study 25772974 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 149
Study 24018083 — intervention group
Group type: EXPERIMENTAL
Intervention: TASKit (Train Anywhere Skill Kit)
Number of subjects: 20
Study 24018083 — intervention group
Group type: COMPARATOR
Intervention: Simulation laboratory training
Number of subjects: 20
Study 22057975 — intervention group
Group type: EXPERIMENTAL
Intervention: HRSD(ANX)
Number of subjects: 3453
Study 22057975 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-C(ANX)
Number of subjects: 3453
Study 22057975 — intervention group
Group type: EXPERIMENTAL
Intervention: HRSD(ANX) and IDS-C(ANX)
Number of subjects: 3453
Study 19481046 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention group (n = 87)
Number of subjects: 146
Study 19481046 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 146
Study 17230081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured epithelial autograft
Number of subjects: 8
Study 17230081 — intervention group
Group type: COMPARATOR
Intervention: Dulbecco's Modified Eagle's Medium (Control)
Number of subjects: 8
Study 15007374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine instillation enhanced by electromotive drug administration (EMDA)
Number of subjects: 28
Study 15007374 — intervention group
Group type: COMPARATOR
Intervention: Conventional lidocaine instillation
Number of subjects: 28
Study 15007374 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia (lidocaine instillation)
Number of subjects: 28
Study 11441406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic aneurysm resection
Number of subjects: 48
Study 11441406 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 48
Study 9893772 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous antibiotic therapy with cefamandole 1 g i.v. every 6 h for 7 days
Number of subjects: 95
Study 9893772 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated intravenous therapy with cefamandole (1 g i.v. every 6 h for 2 days) followed by oral therapy with cefaclor (500 mg every 8 h for 5 days)
Number of subjects: 95
Study 8031068 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids in didanosine tablets
Number of subjects: 12
Study 8031068 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 300 mg isoniazid
Number of subjects: 12
Study 2544345 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 100 micrograms/kg
Number of subjects: 8
Study 2544345 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 250 micrograms/kg
Number of subjects: 8
Study 2544345 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 25 micrograms/kg
Number of subjects: 8
Study 2544345 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 2544345 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (all doses)
Number of subjects: 8
Study 2544345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-pressor test
Number of subjects: 8
Study 31129760 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental 1 (Exp 1; symptom monitoring + report)
Number of subjects: 249
Study 31129760 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental 2 (Exp 2; symptom monitoring + report + ONS PEP–guided evidence‐based symptom management education)
Number of subjects: 249
Study 31129760 — intervention group
Group type: COMPARATOR
Intervention: Control (symptom monitoring)
Number of subjects: 249
Study 30621679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive forcing tool
Number of subjects: 76
Study 30621679 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 29179134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy combined with nimotuzumab
Number of subjects: 107
Study 29179134 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (Control)
Number of subjects: 107
Study 25894531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 400 μg of salbutamol
Number of subjects: 69
Study 25894531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 24515980 — intervention group
Group type: EXPERIMENTAL
Intervention: Obliteration of nasal cavity and bilateral sinuses with bone cement (experimental group)
Number of subjects: 8
Study 24515980 — intervention group
Group type: COMPARATOR
Intervention: Native sinus architecture (control group)
Number of subjects: 8
Study 22950546 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level of transference intervention
Number of subjects: 100
Study 22950546 — intervention group
Group type: COMPARATOR
Intervention: No transference intervention
Number of subjects: 100
Study 20332469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive tutored pelvic training program (group A)
Number of subjects: 332
Study 20332469 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises performed by patients on their own (group B)
Number of subjects: 332
Study 17346304 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (150 mg/day), n = 34
Number of subjects: 60
Study 17346304 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 26
Number of subjects: 60
Study 16291103 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers' Compensation (WC)
Number of subjects: 531
Study 16291103 — intervention group
Group type: COMPARATOR
Intervention: Personal Injury (non-WC)
Number of subjects: 531
Study 12016602 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg hyperbaric bupivacaine
Number of subjects: 40
Study 12016602 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine
Number of subjects: 40
Study 12016602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg hyperbaric bupivacaine
Number of subjects: 40
Study 12016602 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg hyperbaric bupivacaine
Number of subjects: 40
Study 10440603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 12
Study 10440603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg three times daily
Number of subjects: 12
Study 10440603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg twice daily
Number of subjects: 12
Study 10440603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 12
Study 10440603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 12
Study 10440603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7757359 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula fed babies on high lactose content
Number of subjects: 66
Study 7757359 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula fed babies on low lactose content
Number of subjects: 66
Study 7757359 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without lactose intolerance)
Number of subjects: 66
Study 2186587 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of 8 g fosfomycin and 1 g metronidazole at induction of anaesthesia (Group 1)
Number of subjects: 149
Study 2186587 — intervention group
Group type: COMPARATOR
Intervention: Bacitracin 250 mg plus neomycin 250 mg (as four tablets on three occasions over two days), metronidazole 500 mg tablets three times a day for one day, and ampicillin 1 g intravenously at induction of anaesthesia (Group 2)
Number of subjects: 149
Study 2186587 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate among evaluable patients
Number of subjects: 149
Study 2186587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality related to infective complications
Number of subjects: 149
Study 6243242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cyclophosphamide, methotrexate, vincristine) and radiation therapy
Number of subjects: 258
Study 6243242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 258
Study 6243242 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic whole brain irradiation
Number of subjects: 258
Study 6243242 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and radiation therapy
Number of subjects: 258
Study 30787647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 24
Study 30787647 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 27402397 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual retelling condition
Number of subjects: 0
Study 27402397 — intervention group
Group type: EXPERIMENTAL
Intervention: Free retelling condition
Number of subjects: 0
Study 27402397 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional retelling condition
Number of subjects: 0
Study 27402397 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 27402397 — intervention group
Group type: EXPERIMENTAL
Intervention: All three retelling conditions
Number of subjects: 0
Study 25826704 — intervention group
Group type: EXPERIMENTAL
Intervention: UP4FUN intervention (1-2 school lessons per week for 6 weeks)
Number of subjects: 3147
Study 25826704 — intervention group
Group type: EXPERIMENTAL
Intervention: UP4FUN intervention
Number of subjects: 3147
Study 25826704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3147
Study 24187863 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianjining granules and Western Medicine (prednisone or pyridostigmine bromide)
Number of subjects: 60
Study 24187863 — intervention group
Group type: COMPARATOR
Intervention: Jianjining granules
Number of subjects: 60
Study 21860296 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (hands-on vaginal delivery simulation)
Number of subjects: 113
Study 21860296 — intervention group
Group type: COMPARATOR
Intervention: Lecture only (traditional lecture on performing a vaginal delivery)
Number of subjects: 113
Study 19031073 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 0
Study 19031073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17824291 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (477.5 +/- 143.7 mg/d)
Number of subjects: 80
Study 17824291 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (65.9 +/- 17.7 mg)
Number of subjects: 80
Study 17824291 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (11.9 +/- 4.0 mg)
Number of subjects: 80
Study 17824291 — intervention group
Group type: COMPARATOR
Intervention: No sartan treatment (Control group)
Number of subjects: 80
Study 15232456 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (two-dose regime)
Number of subjects: 40
Study 15232456 — intervention group
Group type: COMPARATOR
Intervention: Autologous donation
Number of subjects: 40
Study 11686355 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily low molecular weight heparin
Number of subjects: 1522
Study 11686355 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily low molecular weight heparin
Number of subjects: 1522
Study 9645829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25.0 mg/d) with the addition of atenolol (25-50 mg/d) or reserpine (0.05-0.10 mg/d) if needed
Number of subjects: 4336